A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

Clinical Cancer Research

Volumn 10, Issue 5, 2004, Pages 1670-1677

  Kirkwood, John M ^a   Manola, Judith ^b   Ibrahim, Joseph ^c   Sondak, Vernon ^d   Ernstoff, Marc S ^e   Rao, Uma ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c IL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; ULCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1842533233     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1103-3     Document Type: Article

References (8)

1. Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., and Blum, R. H. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol., 14: 7-17, 1996.
2. Kirkwood, J. M., Ibrahim, J. G., Sondak, V. K., Richards, J., Flaherty, L. E., Ernstoff, M. S., Smith, T. J., Rao, U. N. M., Steele, M., and Blum, H. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J. Clin. Oncol., 18: 2444-2458, 2000.
3. Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., and Rao, U. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J. Clin. Oncol., 19: 2370-2380, 2001.
4. Balch, C. M., Buzaid, A. C., Soong, S-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Jr., Kirkwood, J. M., McMasters, K. M., Mihm, M. F., Morton, D. L., Reintgen, D. S., Ross, M. I., Sober, A., Thompson, J. A., and Thompson, J. F. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol., 19: 3635-3648, 2001.
5. Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., and Chapman, P. B. High-dose interferon α-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J. Clin. Oncol., 19: 1430-1436, 2001.
6. Kirkwood, J. M., Richards, T., Zarour, H., Sosman, J., Ernstoff, M., Whiteside, T. L., Ibrahim, J., Blum, R., Wieand, H. S., and Mascari, R. Immunomodulatory effects of high- and low-dose IFNα2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of Intergroup Adjuvant Trial E1690. Cancer (Phila.), 95: 1101-1112, 2002.
7. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
8. Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B (Methodological), 34: 187-220, 1972.